Regulus Receives FDA Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport SyndromeJuly 21, 2014 8:07 am | News | Comments
Regulus Therapeutics Inc., announced today that the FDA has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
Results From Phase 3 VIVID-DME Trial of EYLEA Injection for the Treatment of Diabetic Macular Edema Show Sustained ImprovementJuly 18, 2014 9:31 am | News | Comments
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that in the Phase 3 VIVID-DME trial of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
A large number of world-renowned AIDS researchers and activists heading to an international AIDS conference in Australia were on board a Malaysian jetliner that was shot down over Ukraine, officials said Friday, as news of their deaths sparked an outpouring of grief across the global scientific community.
The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire.
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre.
Scientists at the Salk Institute have identified a gene responsible for stopping the movement of cancer from the lungs to other parts of the body, indicating a new way to fight one of the world's deadliest cancers.
The road to finding a cure for HIV-1 is not without obstacles. However, thanks to cutting-edge research performed at the George Washington University (GW), Oregon Health & Science University, the University of Rochester, and UC San Francisco, the scientific community is one step closer to finding a viable immunotherapy option for HIV-1, using an immune attack against a fossil virus buried in the genome.
These new glass culture tubes are made from quality borosilicate glass to reduce pH changes and contaminants that can be leached from soda lime glass tubes.
Introducing the Frog-4000, a fully contained purge and trap GC system with analytical capabilities that are comparable to a commercial lab with the advantage of its compact size.
GTCR, a private equity firm, has entered into a definitive agreement to acquire the Cole-Parmer Instrument Company from Thermo Fisher Scientific Inc. for $480 million. Cole-Parmer, headquartered in Vernon Hills, Illinois, is a global manufacturer and distributor of specialty laboratory equipment, instruments and supplies to a diverse range of industries.
The FDA has approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
The Mayo Clinic is testing the safety and effectiveness of taking stem cells from a patient's own fat and injecting them into their spinal fluid to slow the progression of ALS.
The director of the Centers for Disease Control and Prevention acknowledged Wednesday that systemic safety problems have for years plagued federal public health laboratories that handle dangerous germs such as anthrax and bird flu.
No batteries required: Scientists are creating a biological pacemaker by injecting a gene into the hearts of sick pigs that changed ordinary cardiac cells into a special kind that induces a steady heartbeat.
FDA officials said Wednesday the undocumented collection contained 327 carefully packaged vials, listing pathogens like dengue, influenza and rickettsia. Last week the government only disclosed that it had recovered six glass vials of smallpox dating from the 1950s.